glp 1 agonists muscle loss GDF8 and activin A blockade protects against GLP-1–induced while enhancing fat loss in obese male mice and non-human primates Potential Use of GLP-1 and

Delayed gastric emptying, gastroparesis-like symptoms, intestinal obstruction, biliary disease, and pancreatic safety concerns were variably reported, with heterogeneous and sometimes conflicting evidence across studies

For heart failure per se, GLP-1 RAs have a neutral effect on HF hospitalizations (unlike SGLT2 inhibitors which specifically help HF)

GLP-1 agonists work by promoting insulin secretion, which helps maintain blood sugar levels in patients with Type 2 diabetes

In knee OA, clinical data suggest that GLP-1RAs improve pain and function and reduce the risk of surgical intervention

Their ability to suppress appetite, slow gastric emptying, and promote satiety has led to increased levels of weight loss in clinical trials and real-world settings

In addition, the acetaminophen assay could be considered as a better predictor of drug absorption than the other approaches